Overview

NCI Definition [1]:
A 4-aminoquinoline with immunosuppressive, antiautophagy, and antimalarial activities. Although the precise mechanism of action is unknown, hydroxychloroquine may suppress immune function by interfering with the processing and presentation of antigens and the production of cytokines. As a lysosomotropic agent, hydroxychloroquine raises intralysosomal pH, impairing autophagic protein degradation; hydroxychloroquine-mediated accumulation of ineffective autophagosomes may result in cell death in tumor cells reliant on autophagy for survival. In addition, this agent is highly active against the erythrocytic forms of P. vivax and malariae and most strains of P. falciparum but not the gametocytes of P. falciparum.

Hydroxychloroquine has been investigated in 26 clinical trials, of which 21 are open and 5 are closed. Of the trials investigating hydroxychloroquine, 8 are phase 1 (6 open), 7 are phase 1/phase 2 (5 open), and 11 are phase 2 (10 open).

ER Positive, HER2 Deficient Expression, and HER2 Negative are the most frequent biomarker inclusion criteria for hydroxychloroquine clinical trials.

Pancreatic adenocarcinoma, breast carcinoma, and colorectal carcinoma are the most common diseases being investigated in hydroxychloroquine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Hydroxychloroquine
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Hydroxychloroquine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating hydroxychloroquine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
hydroxychloroquine [chemical/ingredient], 7-chloro-4-(4-(n-ethyl-n-beta-hydroxyethylamino)-1-methylbutylamino)quinoline, oxychlorochin, hydroxychlorochin, 7-chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline, 7-chloro-4-[5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl]aminoquinoline, hydroxychloroquine (product), 7-chloro-4-[4-(n-ethyl-n-beta-hydroxyethylamino)-1-methylbutylamino]quinoline, hydroxychloroquine (substance), 118-42-3, hydroxychloroquine, oxychloroquine, hcq, ethanol, 2-((4-((7-chloro-4-quinolinyl)amino)pentyl)ethylamino)-, 2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol, 2-(n-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol, hydroxychloroquine, (+-)-hydroxychloroquine, (±)-hydroxychloroquine, oxichloroquine, hidroxicloroquina, oxichlorochine, hydroxychloroquinum
NCIT ID [1]:
C557
SNOMED ID [1]:
C-56520

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.